KR970005170B1 - Stabilization of 13,14-dihydro-15-keto-prostaglandins - Google Patents

Stabilization of 13,14-dihydro-15-keto-prostaglandins Download PDF

Info

Publication number
KR970005170B1
KR970005170B1 KR89002257A KR890002257A KR970005170B1 KR 970005170 B1 KR970005170 B1 KR 970005170B1 KR 89002257 A KR89002257 A KR 89002257A KR 890002257 A KR890002257 A KR 890002257A KR 970005170 B1 KR970005170 B1 KR 970005170B1
Authority
KR
South Korea
Prior art keywords
dihydro
prostaglandins
keto
stabilization
compound selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR89002257A
Other languages
English (en)
Korean (ko)
Other versions
KR890012654A (ko
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Ueno Seiyaku Oyo Kenkyujo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo Kk filed Critical Ueno Seiyaku Oyo Kenkyujo Kk
Publication of KR890012654A publication Critical patent/KR890012654A/ko
Application granted granted Critical
Publication of KR970005170B1 publication Critical patent/KR970005170B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR89002257A 1988-02-26 1989-02-25 Stabilization of 13,14-dihydro-15-keto-prostaglandins Expired - Fee Related KR970005170B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (ja) 1988-02-26 1988-02-26 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
JP45622/88 1988-02-26

Publications (2)

Publication Number Publication Date
KR890012654A KR890012654A (ko) 1989-09-18
KR970005170B1 true KR970005170B1 (en) 1997-04-14

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR89002257A Expired - Fee Related KR970005170B1 (en) 1988-02-26 1989-02-25 Stabilization of 13,14-dihydro-15-keto-prostaglandins

Country Status (13)

Country Link
EP (1) EP0330511B1 (https=)
JP (1) JP2597629B2 (https=)
KR (1) KR970005170B1 (https=)
AT (1) ATE79260T1 (https=)
AU (1) AU612791B2 (https=)
CA (1) CA1314483C (https=)
DE (1) DE68902401T2 (https=)
ES (1) ES2044087T3 (https=)
GB (1) GB2216004A (https=)
GR (1) GR3005933T3 (https=)
NZ (1) NZ228111A (https=)
OA (1) OA09236A (https=)
ZA (1) ZA891410B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
DE3850676T2 (de) * 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
DE1300150T1 (de) * 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel
EP0410652B1 (en) * 1989-07-27 1995-05-17 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
DE602004023106D1 (de) * 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (ja) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk プロスタグランジンｅの安定化組成物
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
DE3850676T2 (de) 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.

Also Published As

Publication number Publication date
ES2044087T3 (es) 1994-01-01
CA1314483C (en) 1993-03-16
DE68902401D1 (de) 1992-09-17
DE68902401T2 (de) 1992-12-10
AU3029889A (en) 1989-08-31
EP0330511A2 (en) 1989-08-30
GB8904232D0 (en) 1989-04-12
NZ228111A (en) 1991-02-26
AU612791B2 (en) 1991-07-18
KR890012654A (ko) 1989-09-18
ZA891410B (en) 1989-11-29
JPH01221317A (ja) 1989-09-04
EP0330511A3 (en) 1989-10-18
GB2216004A (en) 1989-10-04
OA09236A (en) 1992-06-30
ATE79260T1 (de) 1992-08-15
EP0330511B1 (en) 1992-08-12
GR3005933T3 (https=) 1993-06-07
JP2597629B2 (ja) 1997-04-09

Similar Documents

Publication Publication Date Title
KR970005170B1 (en) Stabilization of 13,14-dihydro-15-keto-prostaglandins
NZ227131A (en) Compositions for improving cognitive function by administering 1,2-oxazole derivatives
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
EP0477021A3 (en) Superfluorescent source stabilization
EP0221728A3 (en) Monosaccharide containing wound healing preparation
IE900709L (en) Pharmaceutical composition which contains a pharmaceutically¹suitable carrier and the compound having the structure¹(7ó,17ó)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-¹3-one
ZA906383B (en) Long active injectable formulations containing triacetin
UA29435C2 (uk) Похідні 3бета-алкенілпенаму та їх фармацевтично прийнятні солі
AU3645489A (en) Insecticidaln'-substituted-n-alkylcarbonyl-n'- acylhydrazines and n'-substituted-n-acyl-n'- alkylcarbonylhydrazines
IL105475A0 (en) Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis
OA09192A (en) "Stabilized sulfur dissolving compositions".
ES2004097A6 (es) Procedimiento de preparacion de un nuevo derivado triciclico denominado acido 5-(3-cloro-6-metil-5,5-dioxo-6,11-dihidro-(c,f)-dibenzo-(1,2)-tiazepin-11-il)amino)-pentanoico
ZA87332B (en) Compositions containing fixed combinations
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
DE3766885D1 (en) Chlorpheniramine therapie.
TW218011B (https=)
GR3021912T3 (en) Fungicidal mixtures.
DE59301187D1 (de) 1,2-Naphthochinon-2-diazid-sulfonsäureester, damit hergestelltes strahlungsempfindliches Gemisch und strahlungsempfindliches Aufzeichnungsmaterial
EP0166056A3 (en) Pharmaceutical dosage unit
MY102026A (en) Antiasthmatic.
AU2403592A (en) 2-aza-2-desamino analogues of 5,8-dideazafolic acid
IL71989A0 (en) L-arginine isoxicamate and pharmaceutical compositions containing it
JPS5655155A (en) Chewing gum
AR242777A1 (es) Compuestos insecticidamente activos derivados de n,n'-dibenzoilhidrazina y composicion que los contienen.

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20030801

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040913

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040913

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000